The invention relates to an antibody, antibody fragment or derivative thereof which specifically recognizes a prion protein and which comprises a complementarity determining region (CDR), a retro-inverso D-peptide of said CDR and/or an anti-idiotypic antibody, antibody fragment or derivative thereof which recognizes said CDR. The invention further concerns a nucleic acid molecule encoding said antibody, antibody fragment or derivative thereof as well as a method for generating an antibody, antibody fragment or derivative thereof that specifically recognizes a prion protein, wherein an antibody that recognizes a specific domain of the prion protein is generated, an antigen-specific amino acid sequence is isolated from said antibody, and an anti-idiotypic antibody, antibody fragment or derivative thereof, which recognizes said antigen-specific amino acid sequence, is generated.

Claims

9 · 1 independent · depth 5

9 granted claims

›1.independentAn isolated antibody or antibody fragment specifically recognizing a prion protein, comprising at least one amino acid sequence selected from a group …+8

›2.↳ 1The antibody or antibody fragment according to claim 1, wherein the complementarity determining region (CDR) is contained in at least one heavy chain …d2+3

›5.↳ 1The antibody or antibody fragment according to claim 1, further comprising at least one signal and/or tag sequence.d2

›6.↳ 1The antibody or antibody fragment according to claim 1, comprising the amino acid sequence according to SEQ ID NO:6.d2

›7.↳ 1A kit comprising the antibody or antibody fragment according to claim 1.d2

›8.↳ 1A pharmaceutical preparation comprising the antibody or antibody fragment according to claim 1.d2

Classifications

2 codes

IPC · International Patent Classification

Section A — Human necessities

A61K39/395

USPC · US Patent Classification

424/130.1

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

4.9 y

1,778 days filing → grant

Office actions

after a restriction

Responses

1 RCE

Examiner

Michelle S Horning

art unit 1648 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 3 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20110098448 A1	28 Apr 2011

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.